作者: Bertrand Toussaint , Xavier Chauchet , Yan Wang , Benoit Polack , Audrey Le Gouëllec
DOI: 10.1586/14760584.2013.836914
关键词:
摘要: In the emerging field of active and specific cancer immunotherapy, strategies using live-attenuated bacterial vectors have matured in terms academic industrial development. Different species can be genetically engineered to deliver antigen APCs with strong adjuvant effects due their microbial origin. Proteic or DNA-encoding delivery routes natural tropisms might differ among species, permitting different applications. After many efforts resolve safety efficacy issues, some firms recently engaged clinical trials live Listeria Salmonella spp. We describe here main technological advances that allowed bacteria become one most promising immunotherapy.